The importance of neoplastic cell content assessment and enrichment by macrodissection in cancer pharmacogenetic testing

J Clin Pathol. 2019 Oct;72(10):721-722. doi: 10.1136/jclinpath-2019-206094. Epub 2019 Aug 2.

Authors

George Joseph Burghel^#^{1

2}, Anne Marie Quinn^#³, Philip Smith^#⁴, Jade Harris¹, Catherine Banks¹, Andrew Wallace¹

Affiliations

¹ Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK.
² School of Health Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
³ Department of Anatomic Pathology, University Hospital Galway, Galway, Ireland.
⁴ Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK philip.smith@mft.nhs.uk.

^# Contributed equally.

PMID: 31375536
DOI: 10.1136/jclinpath-2019-206094

No abstract available

Keywords: cancer genetics; diagnostics; molecular genetics.

Publication types

Case Reports
Letter

MeSH terms

Aged
Dissection / methods*
Humans
Male
Melanoma / drug therapy
Melanoma / enzymology
Melanoma / genetics*
Melanoma / secondary
Middle Aged
Mutation*
Pharmacogenomic Testing*
Pharmacogenomic Variants / genetics*
Precision Medicine
Predictive Value of Tests
Proto-Oncogene Proteins B-raf / genetics*
Reproducibility of Results
Skin Neoplasms / drug therapy
Skin Neoplasms / enzymology
Skin Neoplasms / genetics*
Skin Neoplasms / pathology

Substances

BRAF protein, human
Proto-Oncogene Proteins B-raf